Latham & Watkins represented Octagon Therapeutics in the transaction. Octagon Therapeutics, a preclinical-stage biopharmaceutical company developing targeted medicines for autoimmune disease, has announced the initiation of a...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Alignment Healthcare in the transaction. Alignment Healthcare, Inc.(Alignment Healthcare) (NASDAQ: ALHC), a leading tech-enabled MedicareAdvantage company, has announced the close of an...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Ardelyx, Inc. in the transaction in the transaction. Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Rhythm Pharmaceuticals, Inc. in the transaction, while Morgan, Lewis & Bockius acted as legal advisor to HealthCare Royalty. Rhythm Pharmaceuticals, Inc. (Nasdaq:...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented SoftBank Vision Fund 2 in the transaction. Ventus Therapeutics, a biopharmaceutical company utilizing structural biology and computational tools to identify and develop small molecule...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented CooperCompanies in the transaction. CooperCompanies has announced it has signed a binding letter of intent to acquire Cook Medical’s Reproductive Health business, a manufacturer...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Innocoll Biotherapeutics in the transaction. Innocoll Biotherapeutics plc, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, has announced the successful...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented UPSIDE Foods in transaction. UPSIDE Foods (formerly Memphis Meats), a leading company in the cultivated meat, poultry, and seafood industry, has announced the...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Coherus in the transaction. Coherus BioSciences, Inc. (Coherus or the Company) (Nasdaq: CHRS) has entered into a loan agreement with investment funds managed...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented PROCEPT in the transaction. PROCEPT BioRobotics Corporation, a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology,...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Agenus Inc. in the transaction. Agenus Inc. (Agenus), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented Biomea Fusion, Inc. in the transaction. Biomea Fusion, Inc. (Nasdaq: BMEA) closed its initial public offering of 9 million shares of its...
You must be a Standard 1 Year member to access this content.
